Table 1 Baseline characteristics of 160 patients with AAV
Variables | Values |
|---|---|
Variants of AAV | |
MPA | 85 (53.1) |
GPA | 41 (25.6) |
EGPA | 34 (21.3) |
Demographic data at diagnosis | |
Age (year old) | 55.2 ± 15.1 |
Male gender (N, (%)) | 48 (30.0) |
ANCA at diagnosis (N, (%)) | |
MPO-ANCA (or P-ANCA) | 99 (61.9) |
PR3-ANCA (or C-ANCA) | 27 (16.9) |
MPO-ANCA (or P-ANCA) and PR3-ANCA (or C-ANCA) | 7 (4.4) |
ANCA negative | 41 (25.6) |
Clinical manifestations at diagnosis (N, (%)) | |
General | 71 (44.4) |
Cutaneous | 37 (23.1) |
Mucous membranes/eyes | 12 (7.5) |
Ear Nose Throat (ENT) | 56 (35.0) |
Chest | 84 (52.5) |
Cardiovascular | 45 (28.1) |
Abdominal | 10 (6.3) |
Renal | 95 (59.4) |
Nervous system | 52 (32.5) |
Vasculitis activity and prognostic factors at diagnosis | |
BVAS or BVAS for GPA | 11.9 ± 7.6 |
FFS (2009) | 1.3 ± 1.0 |
Laboratory results at diagnosis | |
WBC (/mm3) | 10,175.6 ± 4758.2 |
Neutrophil (/mm3) | 7227.5 ± 4047.2 |
Lymphocyte (/mm3) | 1564.0 ± 721.2 |
Platelet (×1,000/mm3) | 327.5 ± 141.9 |
ESR (mm/hr) | 60.1 ± 37.4 |
CRP (mg/L) | 43.0 ± 56.5 |
NLR at diagnosis | 6.6 ± 8.3 |
Prognosis | |
Follow-up duration (months) | 55.6 ± 51.5 |
Relapse (N, (%)) | 43 (26.9) |
Death (N, (%)) | 14 (8.8) |